Comparing new drug vs stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a new medicine (AZD0120) can work as well or better than a stem cell transplant for people with newly diagnosed multiple myeloma who have already finished initial treatment. It might help avoid the need for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with multiple myeloma for the first time.
- You have completed 4 to 6 cycles of certain initial treatments (like VRd, DVTd, DRd, or similar).
- Your disease has at least stayed stable or gotten better after initial treatment.
- You are healthy enough (ECOG score 0 or 1) for a stem cell transplant.
- You have not had prior treatments that target BCMA or CD19, like CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
This trial tests two different combinations of medicines in people who still have signs of multiple myeloma after a stem cell transplant. One group gets teclistamab and talquetamab, and the other gets daratumumab and lenalidomide. The goal is to see which works better at removing any remaining cancer cells.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma in patients who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control myeloma and improve survival.
Hear when a new Newly Diagnosed Multiple Myeloma (NDMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.